India Bans Anti-Cold Drug For Children Below 4 After Syrup Deaths Claim

  • 5 months ago
  • News
  • 0

India Bans Anti-Cold Drug For Children Below 4 After Syrup Deaths Claim


The drugs regulator in India has banned the use of an anti-cold drug combination in children aged below four and ordered that drugs should be labelled accordingly, in the wake of the deaths of at least 141 children globally linked to cough syrups.

The regulator said concerns raised about promotion of an unapproved anti-cold drug formulation in infants prompted a discussion and a resulting recommendation to not use the combination for that age group.

The order comes after a spate of child deaths since 2019 that authorities linked to toxic cough syrups made in the country, including at least 141 deaths in Gambia, Uzbekistan and Cameroon since the middle of last year.

Within India, authorities said at least 12 children died and four others were left with severe disabilities in 2019 after consuming domestically-made cough syrups.

India is often dubbed the “world’s pharmacy” due to its supply of life-saving drugs at low prices.

The order by the regulator on the fixed-drug combination (FDC), issued on Dec. 18 and made public on Wednesday, requires drugmakers to label their products with the warning that the “FDC should not be used in children below 4 years of age”.

The fixed drug combination comprises chlorpheniramine maleate and phenylephrine – medication that is often used in syrups or tablets to treat common cold symptoms.

The World Health Organization does not recommend the use of over-the-counter cough syrups or medicines for the treatment of coughs and cold symptoms in children younger than five years of age.

Authorities here have introduced mandatory testing for cough syrup exports since June and stepped up scrutiny of drugmakers. Drugmakers whose cough syrups were linked to child deaths have denied any wrong doing.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

Source link

Join The Discussion

Compare listings